Andere talen Fulcrum Therapeutics, Inc.

Aandelen

FULC

US3596161097

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 29-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
7,08 ^USD	-0,84%		-2,34%	+4,89%

18/03	Fulcrum Therapeutics benoemt Patrick Horn tot medisch directeur	MT
18/03	Fulcrum Therapeutics, Inc. Kondigt wijzigingen in de leiding aan	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium	28/03
Fulcrum Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	25/03
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	22/03
Fulcrum Therapeutics Appoints Patrick Horn as Chief Medical Officer	18/03
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer	18/03
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer	18/03
Fulcrum Therapeutics, Inc. Announces Executive Changes	18/03
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) added to S&P Pharmaceuticals Select Industry Index	18/03
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	08/03
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	08/03
Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference	05/03
GSK : la Dr Jeannie Lee entre au conseil d'administration	29/02
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023	28/02
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023	27/02
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/02
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023	27/02
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET	20/02
Fulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	06/02
Fulcrum Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	08/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Fulcrum Therapeutics, Inc.

Aandelen

FULC

US3596161097

Andere talen

Filters